Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Receptor tyrosine kinase (RTK) inhibitors show limited efficacy in advanced osteosarcoma due to acquired drug resistance.
• Targeting RTK pathways vertically may overcome resistance mechanisms.

Purpose of the Study:

• To investigate the synergistic antitumor activity of combining pazopanib and trametinib in osteosarcoma.
• To elucidate the molecular mechanisms and potential escape pathways involved in this drug combination.

Main Methods:

• In vitro and in vivo studies using osteosarcoma cell lines and xenografts in mice.
• Molecular mechanism investigation using Nanostring technology, western blot, and gene silencing/overexpression experiments.
• Assessment of MAPK-PI3K pathway involvement and specific receptor modulation.

Main Results:

• Pazopanib and trametinib demonstrated synergistic antitumor activity, inducing apoptosis and inhibiting ERK1/2 and Akt pathways.
• The combination down-modulated Ephrin Type-A Receptor 2 (EphA2) and Interleukin-7 Receptor (IL-7R) while inducing mitogen-activated protein-kinase kinase (MAPKK) MEK6.
• EphA2 silencing reduced proliferation and migration; impeding MEK6 up-regulation enhanced the combination's antitumor effect, suggesting MEK6 up-regulation as an escape mechanism.

Conclusions:

• Pazopanib and trametinib exhibit synergistic antitumor effects in osteosarcoma models via ERK and Akt inhibition and EphA2/IL-7R down-modulation.
• MEK6 up-regulation represents a potential escape mechanism that diminishes the combination therapy's efficacy.
• Vertical inhibition targeting RTK pathways offers a viable strategy to enhance osteosarcoma treatment outcomes.